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VRK3-mediated nuclear 
localization of HSP70 prevents 
glutamate excitotoxicity-induced 
apoptosis and Aβ accumulation via 
enhancement of ERK phosphatase 
VHR activity
Haengjin Song1, Wanil Kim1, Sung-Hoon Kim2 & Kyong-Tai Kim1,2
Most of neurodegenerative disorders are associated with protein aggregation. Glutamate-induced 
excitotoxicity and persistent extracellular signal-regulated kinase (ERK) activation are also implicated 
in neurodegenerative diseases. Here, we found that vaccinia-related kinase 3 (VRK3) facilitates nuclear 
localization of glutamate-induced heat shock protein 70 (HSP70). Nuclear HSP70 leads to enhancement 
of vaccinia H1-related phosphatase (VHR) activity via protein-protein interaction rather than its 
molecular chaperone activity, thereby suppressing excessive ERK activation. Moreover, glutamate-
induced ERK activation stimulates the expression of HSP70 and VRK3 at the transcriptional level. 
Downregulation of either VRK3 or HSP70 rendered cells vulnerable to glutamate-induced apoptosis. 
Overexpression of HSP70 fused to a nuclear localization signal attenuated apoptosis more than HSP70 
alone. The importance of nuclear localization of HSP70 in the negative regulation of glutamate-induced 
ERK activation was further confirmed in VRK3-deficient neurons. Importantly, we showed a positive 
correlation between levels of VRK3 and HSP70 in the progression of Alzheimer’s and Parkinson’s 
diseases in humans, and neurons with HSP70 nuclear localization exhibited less Aβ accumulation in 
brains from patients with Alzheimer’s disease. Therefore, HSP70 and VRK3 could potentially serve as 
diagnostic and therapeutic targets in neurodegenerative diseases.
Neurodegenerative disorders, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s 
disease, are characterized by selective loss of neurons in motor, sensory, or cognitive brain areas. Due to the 
accumulation of intracellular inclusions or extracellular protein aggregates in specific brain regions, many neu-
rodegenerative disorders are also known as proteinopathies1. In AD, β -amyloid (Aβ ) plaques and neurofibrillary 
tangles consisting of aggregated Aβ peptide and hyperphosphorylated tau aggregates, respectively, accumulate in 
extracellular and intracellular space2,3. In PD, Lewy bodies containing aggregated α -synuclein are also deposited 
intracellularly4.
Heat shock proteins (HSPs) are the major class of molecular chaperones that interact with and stabilize client 
proteins to maintain their native conformation, thereby preventing protein misfolding and aggregation under 
stress conditions5. HSPs are induced by various stresses such as heat shock, ischemia, hypoxia, heavy metals, 
and amino acid analogs6,7, and many are upregulated in tissue from aged animals and elderly patients with 
neurodegeneration8,9. The HSP70 family, one of the most conserved molecular chaperone families, supports 
the degradation, transport, and dissociation of misfolded protein complexes and prevents aggregation of client 
proteins10–13. In eukaryotes, HSP70 is found in almost all intracellular compartments, including the cytosol, 
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endoplasmic reticulum, and the mitochondria14. The expression of HSP70 is very low under normal physiological 
conditions, but three members of HSP70 family are induced in response to stress6, with heat shock stress particu-
larly inducing their rapid and transient relocation to the nucleus15. A recent study further identified a new HSP70 
transport pathway mediated by the carrier protein Hikeshi under heat shock stress conditions16.
A large body of evidence supports a protective role of HSP70 in humans and animal disease models. For 
example, in AD, HSP70 inhibits Aβ oligomerization, enhances Aβ clearance, restores tau homeostasis, and sup-
presses neuronal apoptosis17–19. In PD, HSP70 enhances α -synuclein refolding and degradation, thereby decreas-
ing α -synuclein aggregate formation and toxicity20. However, beyond its role as a chaperone, the mechanisms by 
which HSP70 functions in cells and exerts neuroprotection are poorly understood.
Persistent activation of extracellular signal-regulated kinase 1/2 (ERK 1/2)-induced neuronal degeneration 
is also implicated in neurodegenerative diseases21,22. ERK 1/2, which belongs to the family of mitogen-activated 
protein kinases (MAPKs), regulates many cytoplasmic and nuclear targets by phosphorylation, and mediates 
several important cellular functions, including proliferation, migration, and differentiation23,24. Although ERK 
1/2 activity is generally involved in cell survival, growing evidence suggests that ERK 1/2 also mediates apoptosis 
depending on the intensity and duration of its activity and subcellular distribution23,24. The regulation of cell 
survival and death relies on the balance between pro- versus anti-apoptotic signals transmitted by ERK 1/223,24. 
Sustained activation of ERK 1/2 causes its translocation to the nucleus and can promote neuronal death via tran-
scriptional regulation25. The active ERK in the nucleus is regulated by vaccinia H1-related phosphatase (VHR) 
that specifically dephosphorylates and inactivates nuclear ERK 1/226,27.
Glutamate, the major excitatory neurotransmitter in the mammalian central nervous system28, has pivotal 
roles in neuronal development, synaptic transmission, and plasticity that underlie learning and memory, emo-
tion, sensation, and motor function; however, glutamate is also involved in neurological diseases29. Excessive acti-
vation of glutamate receptors impairs intracellular calcium homeostasis, increases generation of reactive oxygen 
species, and alters the activation of kinases, including ERK 1/2, and proteases that degrade proteins, membranes, 
and nucleic acids30. This phenomenon, referred to as ‘glutamate neurotoxicity’, results in damage to dendrites and 
even cell death. Although the exact mechanisms that initiate and contribute to the progression of neurodegener-
ation remain unknown, neurodegenerative diseases share common pathological features, such as persistent ERK 
1/2 activation21,22, oxidative stress31, and excitotoxicity30.
In this study, we investigated endogenous protective mechanisms against glutamate-induced neurotoxicity. 
We found that VRK3 interacts with glutamate-induced HSP70 and promotes its nuclear localization. Nuclear 
HSP70 enhances VHR phosphatase activity and leads to attenuation of persistent ERK activation and cell death 
caused by glutamate excitotoxicity. Results from VRK3-deficient neurons further confirmed the role of HSP70 
nuclear localization in the regulation of glutamate-induced prolonged ERK activation that triggers cell death. 
Furthermore, in brains of AD and PD patients, we observed increased levels of VRK3 and HSP70 and the pres-
ence of Aβ plaques that were deficient in nuclear HSP70, suggesting that nuclear HSP70 protects cells from 
protein aggregation-induced neuronal death. Hence, we conclude that VRK3-mediated nuclear localization of 
HSP70 plays a neuroprotective role by reducing glutamate-induced prolonged ERK activity that causes cell death.
Results
HSP70 interactes with and enhances VHR phosphatase activity. We identified VHR and VRK3 
as binding partners of HSP70 by performing co-immunoprecipitation assay using SH-SY5Y cell lysates overex-
pressing the stress-inducible HSP70 form, HSP70A1A (Fig. 1a). VHR has a role in specific dephosphorylation 
and inactivation of nuclear ERK26,27, and VRK3 acts as a mediator protein32. We first examined the relationship 
between HSP70 and VHR. Inducible HSP70 immunoprecipitated with an antibody against anti-HA in gluta-
mate-treated SH-SY5Y cells expressing HA-VHR (Fig. 1b). In addition, the interaction of endogenous VHR 
with inducible HSP70 was further confirmed in glutamate-treated SH-SY5Y cells (Fig. 1c). Glutamate treatment 
induced nuclear translocation of both FLAG-tagged HSP70 and HA-tagged VHR, proteins that were predomi-
nantly localized in the cytoplasm under normal, non-stressed conditions (Fig. 1d). HSP70 and VHR were mainly 
co-localized in the nucleus of glutamate-treated SH-SY5Y cells. This data indicates that glutamate-induced HSP70 
interacts with VHR predominantly in the nucleus.
HSP70 consists of two highly conserved domains: the N-terminal nucleotide binding domain and the 
C-terminal substrate binding domain33. To clarify whether HSP70 directly interacts with VHR, and to identify 
the specific VHR-binding region in HSP70, we conducted the GST pull down assay using GST-tagged full-length 
HSP70 and its fragments (F1, amino acids 1-380; F2, amino acids 381-537; F3, amino acids 538-642; Fig. 1e). 
GST-HSP70, but not GST control, specifically associated with VHR (Fig. 1f). Also, HSP70 F1 and F3 fragments, 
but not the F2 fragment, bound to VHR. To determine whether the binding of HSP70 affects VHR activity, we 
performed in vitro phosphatase assay (Fig. 1g–i). Compared with VHR alone, the addition of HSP70 induced a 
2-fold increase in VHR phosphatase activity when either p-nitrophenyl phosphate (pNPP; Fig. 1g) or purified 
recombinant p-ERK2 protein (Fig. 1h,i) was used as a substrate. These results indicate that HSP70 enhances VHR 
phosphatase activity.
VRK3 promotes nuclear localization of HSP70 induced by glutamate. We next examined the 
relationship between HSP70 and VRK3. The interaction of these two proteins confirmed by mass spectrometry 
analysis on FLAG-VRK3- expressing 293FT cell lysates immunoprecipitated with an antibody against anti-FLAG 
(Fig. 2a). To identify the VRK3-binding region in HSP70, we expressed HA-tagged full length HSP70 or its frag-
ments along with FLAG-VRK3 in SH-SY5Y cells (Fig. 2b). Although it has a different electrophoretic mobility 
than that seen in the input, HA-tagged full length HSP70 retrieved in the immunoprecipitation. The HSP70 F2 
fragment, which contains the substrate binding domain, was found to interact with VRK3 (Fig. 2b). For the inter-
action to occur, nuclear translocation of HSP70 is necessary, because VRK3 is mainly localized in the nucleus 
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Figure 1. HSP70 interacts with and enhances VHR phosphatase activity. (a) Endogenous VHR and VRK3 
immunoprecipitated with an antibody against anti-FLAG in SH-SY5Y cell lysates expressing FLAG- HSP70.  
(b) Endogenous HSP70 immunoprecipitated with an antibody against anti-HA in glutamate-treated  
SH-SY5Y cell lysates expressing HA-VHR. (c) Endogenous HSP70 immunoprecipitated with endogenous 
VHR in glutamate-treated SH-SY5Y cell lysates. (d) FLAG-tagged HSP70 and HA-tagged VHR were mainly 
co-localized in the nucleus of SH-SY5Y cells treated with glutamate. Scale bar, 20 μ m. (e) Domain structure of 
HSP70 and schematic representation of HSP70 fragments. (f) HSP70 bound to VHR with its ATPase domain and 
a functionally unknown region (C-terminal region). (g) A 2-fold increase in VHR phosphatase activity by HSP70. 
In vitro VHR phosphatase assay was performed using HSP70 with pNPP. Values are shown as mean ± standard 
deviation (s.d.), n = 3. Student’s t-tests, ***P < 0.001. (h) HSP70 enhanced VHR phosphatase activity in a 
chaperone activity-independent manner. In vitro VHR phosphatase assay was performed using HSP70 with 
recombinant p-ERK2. (i) Quantification of the percentage of p-ERK2 versus total ERK2 as in (h). Values are 
normalized to p-ERK2-only control and shown as mean ± s.d., n = 3. Student’s t-tests, *P < 0.05, **P < 0.01.
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due to its nuclear localization signal (NLS)34. HSPs are induced by various stresses6,7 and especially, in response 
to heat shock stress, HSP70 are rapidly expressed and transiently relocated from cytoplasm into the nucleus6. To 
verify whether treatment with excessive glutamate induces nuclear translocation of HSP70, we tested cytoplas-
mic and nucleoplasmic fractions of non-treated and glutamate-treated SH-SY5Y cells (Fig. 2c). Nuclear HSP70 
was markedly increased in cells treated with glutamate compared with control. In addition, co-localization of 
HA-tagged VRK3 and endogenous HSP70 was detected in glutamate-treated SH-SY5Y cells (Fig. 2d). The amount 
of nuclear HSP70 was increased in cells overexpressing VRK3. To clarify whether VRK3 binding affects nuclear 
localization of HSP70, we analyzed cytoplasmic and nucleoplasmic fractions of glutamate-treated SH-SY5Y 
cells (Fig. 2e, Supplementary Fig. S1). VRK3 promoted nuclear localization of glutamate-induced HSP70 in 
dose-dependent manner (Fig. 2e), compared with control which showed no differences in levels of nuclear HSP70 
between the groups (Supplementary Fig. S1). In contrast, cells reducing VRK3 expression using siRNAs showed 
markedly suppressed nuclear localization of glutamate-induced HSP70 (Fig. 2f,g). We also tested the effects of 
Figure 2. VRK3 promotes nuclear localization of HSP70 in glutamate-treated SH-SY5Y cells. (a) HSP70 
bound to FLAG-tagged VRK3 in HEK2FT cells. (b) FLAG-tagged VRK3 bound to the HA-tagged substrate 
binding domain of HSP70 with high affinity. (c) Nuclear localization of endogenous HSP70 was increased in 
glutamate-treated SH-SY5Y cells. (d) HA-tagged VRK3 and endogenous HSP70 were co-localized in glutamate-
treated SH-SY5Y cells. The dotted lines represent the boundary between nucleus and cytoplasm; White 
arrowheads highlight cells expressed relatively low level of HA-VRK3. Scale bar, 20 μ m. (e) Overexpression 
of FLAG-tagged VRK3 facilitated nuclear localization of HSP70 in dose-dependent manner. (f) Inhibition of 
glutamate-induced nuclear localization of HSP70 in cells with VRK3 knockdown. (g) Quantification of the 
levels of nuclear HSP70 as in (f). Values are normalized to control and shown as mean ± s.d., n = 3. Student’s 
t-tests, **P < 0.01. (h) Glutamate-induced nuclear localization of HSP70 was suppressed by pre-treatment with 
importazole, a nuclear transport receptor importin-β inhibitor. (i) Nuclear localization of HSP70 facilitated by 
FLAG-tagged VRK3 was also suppressed by importazole treatment.
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overexpression or knockdown of VHR on nuclear localization of HSP70 in glutamate-treated SH-SY5Y cells 
(Supplementary Fig. S2a,b). There were no significant differences in levels of nuclear HSP70 between the groups. 
Together, these findings reveal that VRK3 facilitates glutamate-induced nuclear localization of HSP70.
Regulation of the nucleocytoplasmic protein transport is mediated by members of the importin β family35. 
Importin β family carriers interact with their specific cargos and facilitates transfer to the nucleus through the 
nuclear pore complex (NPC) upon binding35. To elucidate the mechanism of enhanced nuclear localization of 
HSP70 by VRK3, we pre-treated cells with importazole, an inhibitor of importin-β transport receptors, before 
glutamate treatment and then analyzed cytoplasmic and nucleoplasmic fractions of SH-SY5Y cells (Fig. 2h,i). 
Pre-treatment of the cells with importazole resulted in suppression of glutamate-induced HSP70 nuclear trans-
location, even though the expression of endogenous VRK3 was increased (Fig. 2h). Consistent with previous 
results, VRK3 overexpression promoted nuclear localization of HSP70, however, pre-treatment with importazole 
resulting in reduced nuclear HSP70 (Fig. 2i). Taken together, this data indicates that VRK3 supports nuclear 
retention of glutamate-induced HSP70 rather than assisting in its translocation to the nucleus.
Glutamate-induced active ERK stimulates the gene expression of both HSP70 and VRK3, and 
inhibits its sustained activity that triggers cell death. Although ERK is associated with cell survival, 
it is also linked to cell death. ERK 1/2 determines cell fate based on its abundance, duration of activation, and sub-
cellular distribution23,24. Several studies have focused on the detrimental role of persistent ERK activation under 
stress36–38. Furthermore, prolonged ERK activation is implicated in glutamate-induced cell death37.
Previous studies have shown that ERK activation induced by phorbol 12-myristate 13-acetate increases VRK3 
expression32. Before investigating the physiological significance of both HSP70 and VRK3 in the regulation of 
ERK activation, we explored whether glutamate-induced ERK activity affects the expression of HSP70 and VRK3. 
In agreement with previous findings, treatment with glutamate stimulated ERK activation (Fig. 3a). Increased 
ERK phosphorylation reached a peak 1–2 h after glutamate treatment and returned to basal levels within 6 h. 
Moreover, we detected positive correlation between ERK activity and the protein levels of HSP70 and VRK3. 
To confirm an association between the activation status of ERK and the levels of HSP70 and VRK3 proteins, we 
pretreated SH-SY5Y cells with PD98059, a specific MEK/ERK inhibitor, before glutamate treatment (Fig. 3b). 
Blocking ERK phosphorylation resulted in a delayed increase in both HSP70 and VRK3 proteins upon glutamate 
exposure. To clarify whether the elevation of HSP70 and VRK3 protein levels followed by ERK activation is due 
to upregulation of endogenous mRNA levels, we performed quantitative real-time RT-PCR using SH-SY5Y cells 
pretreated with either vehicle or PD98059 before glutamate exposure (Fig. 3c,d). Pharmacological inhibition 
of ERK activation delayed mRNA expression of both HSP70 and VRK3 following glutamate treatment com-
pared with control. After initial peak, there were no significant differences in gene expression of both HSP70 and 
VRK3 between the groups. These results indicate that glutamate-induced active ERK stimulates HSP70 and VRK3 
expression at the transcriptional level.
Upon sustained activation, ERK 1/2 translocates to the nucleus and regulates several transcription factors, 
resulting in the expression of pro-apoptotic proteins25. Our results showed that glutamate-induced HSP70 is relo-
cated from cytoplasm into the nucleus. To examine whether translocated HSP70 regulates nuclear ERK through 
the enhancement of VHR phosphatase activity, we analyzed the nucleoplasmic fraction of glutamate-treated 
SH-SY5Y cells (Fig. 3e). In agreement with previous findings, excessive active ERK stimulated by glutamate trans-
located into the nucleus, and active nuclear ERK levels were increased for up to 2 h. The levels of both endogenous 
HSP70 and VRK3 were also increased in the nucleus after glutamate treatment. Results from immunocytochem-
istry using glutamate-treated SH-SY5Y cells expressing HA-tagged HSP70 revealed that overexpression of HSP70 
leads to decrease of glutamate-induced activation of ERK (Fig. 3f). Cells showed prolonged ERK activation fol-
lowed by increased level of cleaved caspase 3, an active form of caspase 3 that triggers apoptosis by degrading 
cytoskeletal and nuclear proteins39,40. The cleavage of caspase 3 was markedly suppressed in cells overexpressing 
HSP70 (Fig. 3g), indicating that HSP70 inhibits neuronal cell death via prevention of glutamate-induced pro-
longed ERK activation in the nucleus. Taken together, these data indicate that glutamate-induced active ERK 
transcriptionally upregulates the expression of HSP70 and VRK3, and suppresses its prolonged activity that 
causes cell death.
VRK3-mediated nuclear localization of HSP70 is important for suppression of glutamate-induced 
prolonged ERK activation and subsequent cell death. To ascertain the involvement of HSP70 and 
VRK3 in reducing glutamate-induced persistent ERK activation, we examined glutamate-treated SH-SY5Y cells 
after downregulation of either VRK3 or HSP70 expression by siRNA (Fig. 4a–c). ERK activation in SH-SY5Y 
cells with either HSP70 or VRK3 knockdown was sustained for at least 6 h after glutamate exposure com-
pared with control (Fig. 4a,b). Interestingly, sustained ERK activation led to increased expression of VRK3 
in HSP70-downregulated SH-SY5Y cells, indicating the existence of a compensatory mechanism between 
HSP70 and VRK3 in the regulation of ERK activation. In addition, VRK3-downregulating cells which showed 
low levels of active ERK compared with cells with HSP70 knockdown were more susceptible to glutamate 
excitotoxicity-induced cell death, suggesting that VRK3 has another crucial role for survival.
We conducted TUNEL assay to verify whether the suppression of prolonged ERK activation by HSP70 and 
VRK3 attenuates glutamate-induced cell death. Downregulation of either HSP70 or VRK3 increased the number 
of TUNEL-positive cells in glutamate-treated SH-SY5Y cells (Fig. 4c). These results indicate that HSP70 and 
VRK3 inhibit glutamate-induced prolonged ERK activation that triggers neuronal cell death.
To confirm whether nuclear localization of HSP70 is required to decrease glutamate-induced ERK activation, 
we examined cytoplasmic and nucleoplasmic fractions of SH-SY5Y cells (Fig. 4d). Levels of active ERK were 
markedly reduced after increased nuclear localization of HSP70 along with VRK3. We created a construct capable 
of redirecting HSP70 to the nucleus through the fusion of three tandem repeats of NLS peptides of SV40 large T 
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Figure 3. Glutamate-induced ERK activation stimulates the expression of both HSP70 and VRK3 to 
suppress its sustained activity that causes cell death. (a) The protein levels of HSP70 and VRK3 were 
positively correlated with ERK activity. (b) Blocking ERK phosphorylation using PD98059, a specific MEK/
ERK inhibitor, delayed an increase in both HSP70 and VRK3 protein upon glutamate exposure. (c,d) Inhibition 
of ERK activation delayed mRNA expression of HSP70 (c) and VRK3 (d) following glutamate treatment. The 
mRNA levels of endogenous genes were detected by quantitative real-time PCR. Values are normalized to 
RPL32 and shown as mean ± s.d., n = 3. Student’s t-tests, **P < 0.01, ***P < 0.001. (e) Nuclear translocation 
of active ERK and increased levels of both endogenous HSP70 and VRK3 were observed in glutamate-treated 
SH-SY5Y cells. (f) HSP70-mediated downregulation of p-ERK prevented glutamate-induced apoptosis. White 
arrowheads highlight cleaved caspase-3-positive cells. Scale bar, 20 μ m. (g) Glutamate-induced apoptosis was 
suppressed in HSP70-overexpressing SH-SY5Y cells. White arrows show HSP70-overexpressing cells. White 
arrowheads highlight cleaved caspase-3-positive cells. Scale bar, 20 μ m.
www.nature.com/scientificreports/
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antigen (PKKKRKV)41 to the C-terminus of HSP70 (Fig. 4e). HSP70 fused to NLS decreased glutamate-induced 
ERK activation more efficiently than HSP70 alone. These results were further supported by immunofluores-
cence analysis (Fig. 4f,g). Notably, when HSP70 was highly concentrated in the nucleus, activate ERK in both 
the cytoplasm and nucleus was decreased. Moreover, TUNEL staining showed that HSP70 fused to NLS inhibits 
glutamate-induced apoptosis more effectively than HSP70 alone (Fig. 4h). Taken together, these results indicate 
that VRK3-mediated nuclear localization of HSP70 is critical for suppressing glutamate-induced persistent ERK 
activation and excitotoxicity-evoked neuronal cell death.
Figure 4. VRK3-mediated nuclear localization of HSP70 is crucial for inhibition of glutamate-induced 
prolonged ERK activation and subsequent cell death. (a) Glutamate-induced persistent ERK activation in SH-
SY5Y cells after downregulation of either VRK3 or HSP70. (b) Quantification of the levels of p-ERK versus total 
ERK as in (a). Values are normalized to GAPDH and shown as mean ± s.d., n = 3. Student’s t-tests, **P < 0.01. 
(c) Reducing expression of either HSP70 or VRK3 rendered cells vulnerable to glutamate-induced apoptosis. 
Representative images of TUNEL-positive cells. Scale bar, 20 μ m. (d) Suppression of glutamate-induced ERK 
activation depended on VRK3-mediated nuclear localization of HSP70. (e) HSP70 fused to NLS decreased 
glutamate-induced ERK activation more efficiently than HSP70 alone. (f) HSP70 nuclear localization was 
important for the downregulation of glutamate-induced ERK activation. Scale bar, 20 μ m. (g) Quantification of 
p-ERK intensity as in (f). Values are normalized to control and shown as mean ± s.d., n ≥ 30 for each sample. 
Student’s t-tests, **P < 0.01. (h) HSP70 fused to NLS prevented glutamate-induced apoptosis more effectively 
that HSP70 alone. Representative images of TUNEL-positive cells. Scale bar, 20 μ m.
www.nature.com/scientificreports/
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To further determine whether the interaction between the HSP70 F2 fragment and VRK3 is sufficient for 
HSP70 nuclear localization and subsequent downregulation of glutamate-induced ERK activation, we examined 
the nucleoplasmic fraction of glutamate-treated SH-SY5Y cells (Supplementary Fig. S3). Nuclear localization 
of HSP70 F2 fragment was increased along with VRK3. However, the F2 fragment did not have an effect on 
glutamate-evoked ERK activation. This observation is consistent with our finding that the HSP70 F2 fragment 
had almost no binding affinity towards VHR.
Neuroprotective role of HSP70 and VRK3 against glutamate excitotoxicity in mouse cortical 
neurons. To determine whether HSP70 and VRK3 affect the regulation of nuclear ERK in mouse cortical neu-
rons treated with glutamate, cortical neurons obtained at postnatal day 0.5 were purified and cultured for 5 days. 
Cultured cells were considered neurons based on the presence of MAP2- and NeuN-positive projections (Fig. 5a). 
In agreement with previous findings glutamate-evoked ERK activation was detected in mouse cortical neurons 
(Fig. 5b). In addition, glutamate treatment significantly increased the number of cleaved caspase-3-positive neu-
rons (Fig. 5c,d), indicating that glutamate-induced excitotoxicity causes persistent ERK activation that triggers 
neuronal cell death.
Consistent with previous results, overexpression of HSP70 attenuated persistent ERK activation induced by 
glutamate in mouse cortical neurons (Fig. 5e,f). To directly examine the functional importance of VRK3 in vivo, 
we have used VRK3-deficient mice generated by targeted gene disruption in embryonic stem cells (Fig. 5g–j). 
Despite induction of HSP70, VRK3-deficient neurons showed sustained ERK activation (Fig. 5g) and markedly 
decreased cell viability relative to control (Fig. 5h), indicating that both HSP70 and VRK3 are essential for main-
taining neuronal viability against glutamate-evoked persistent ERK activation. The importance of nuclear local-
ization of HSP70 in the regulation of glutamate-induced ERK activation and the role of VRK3 as a facilitator of 
HSP70 nuclear localization were further supported by immunofluorescence analysis of VRK3-deficient neurons 
(Fig. 5i,j). Neurons overexpressing VRK3 exhibited markedly reduced ERK activation compared with control. 
Moreover, HSP70 fused to NLS decreased glutamate-induced ERK activation more efficiently than HSP70 alone, 
indicating that VRK3-mediated HSP70 nuclear localization and subsequent downregulation of ERK activation 
are required to protect neurons from glutamate-evoked excitotoxicity.
Increased expression and nuclear localization of HSP70 suppress Aβ accumulation and neuronal 
cell death in brains of AD and PD patients. Persistent ERK 1/2 activation and glutamate neurotoxicity 
are pathological features shared among neurodegenerative diseases21,22,30. Several studies show that HSP70 is 
elevated in brain tissue from elderly patients with neurodegeneration8,9. To determine whether our findings have 
clinical relevance, we analyzed brain lysates from AD and PD patients (Supplementary Table S1). In accordance 
with previous reports, HSP70 expression and p-ERK levels were significantly increased in brains of AD and PD 
patients (Fig. 6a,b). The mean values of VRK3 was also increased in AD and PD brains compared with normal 
control brains, but statistically insignificant.
Recent evidence suggests that neurodegenerative pathology is transmissible from cell to cell, and the spread 
of pathological proteins leads to overwhelming proteolytic stress in neurons, causing damage to specific brain 
regions and contributing to disease progression42–44. To determine whether VRK3-mediated HSP70 nuclear local-
ization and subsequent downregulation of ERK activation defend against proteolytic stress by reducing aggregate 
toxicity, we examined prefrontal cortex sections from AD patients (Fig. 6c, Supplementary Table S2). Consistent 
with previous studies that showed a strong positive correlation between Aβ plaque deposition and neuronal cell 
death45, cleaved caspase-3 highly colocalized with Aβ plaque in AD brains (Fig. 6c). Interestingly, regions with 
high HSP70 expression exhibited less Aβ accumulation, and HSP70 predominantly localized in cell nuclei. These 
results indicate that increased expression of HSP70 and its nuclear localization mediated by VRK3 can contribute 
to neuronal protection from cell death in the brains of AD and PD patients.
Discussion
Excitotoxicity caused by excessive activation of glutamate receptors, impairment of intracellular calcium home-
ostasis, increased reactive oxygen species, persistent ERK activation, and protein aggregation are implicated in 
neurodegenerative diseases such as AD and PD25,30,37,46–48. However, the endogenous protective mechanisms 
against neurodegeneration are poorly understood. Here, we showed that VRK3 facilitates nuclear localization of 
HSP70 induced by glutamate stimulation, and nuclear HSP70 enhances VHR phosphatase activity through direct 
binding, leading to suppression of sustained ERK activation and apoptotic cell death (Fig. 6d).
Many previous studies on the cytoprotective role of HSP70 have focused on its mediation of protein folding, 
degradation, and transport5,49. However, in addition to protein quality control, HSP70 may have other roles, such 
as the regulation of signaling pathways. Recent studies show that HSP70 modulates both caspase-dependent and 
-independent apoptosis by direct protein-protein interaction. For example, HSP70 interacts with and neutral-
izes Apoptosis-inducing factor (AIF), a mitochondrial intermembrane protein that translocates into the nucleus 
and triggers chromatin condensation and large-scale (~50 kbp) DNA fragmentation50. HSP70 can also directly 
bind to Apoptotic protease activation factor 1 (APAF1), which prevents APAF1 oligomerization and inhibits 
procaspase-9 recruitment to the apoptosome51,52. Several convincing reports illustrate the involvement of HSP70 
in MAPK signaling. HSP70 suppressed ERK activation by inhibiting Mitogen-activated protein kinase kinase 
(MEK 1/2) activation53. HSP70 also inhibits RAF proto-oncogene serine/threonine-protein kinase-mediated ERK 
activation through competitive interactions to Bcl2-associated athanogene 1 (BAG1) that binds to and activates a 
RAF1 kinase54. The present study identified a novel regulatory mechanism of MAPK pathways by HSP70. Along 
with VRK3, nuclear translocated HSP70 directly binds to and enhances VHR phosphatase activity, leading to the 
suppression of glutamate-induced excessive ERK activation. Because HSP70 chaperone activity is regulated by 
ATP hydrolysis that controls substrate binding and release through conformational changes55, our present in vitro 
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Figure 5. Neuroprotective role of HSP70 and VRK3 against glutamate in mouse cortical neurons. (a) Primary 
cultured mouse cortical neurons expressed MAP2 and NeuN. Scale bar, 20 μ m. (b) Glutamate induced ERK 
activation in mouse cortical neurons. (c) Glutamate triggered apoptosis of mouse cortical neurons. Representative 
images of cleaved caspase-3-positive cells and NeuN-stained cell nuclei (blue). Scale bar, 20 μ m. (d) Quantification 
of the percentage of cleaved caspase-3-positive neurons treated in (c). Values are normalized to untreated 
controls and shown as mean ± s.d., n = 3. Student’s t-test, **P < 0.01. (e) Overexpression of HSP70 downregulated 
glutamate-induced persistent ERK activation. Scale bar, 20 μ m. (f) Quantification of p-ERK intensity in mouse 
cortical neurons expressing HA (mock) or HA-HSP70 as in (e). Values are normalized to HA-controls, and shown 
as mean ± s.d., n ≥ 30 for each sample. Student’s t-test, *P < 0.05. (g) VRK3-deficient mice exhibited excessive ERK 
activation induced by glutamate treatment. (h) VRK3-deficient mice showed increased sensitivity to glutamate-
induced apoptosis. Values are normalized to untreated controls and shown as mean ± s.d., n = 3. Student’s t-test, 
**P < 0.01, ***P < 0.001. (i) Nuclear localization of HSP70 by either VRK3 or fused NLS is critical for suppressing 
glutamate-induced persistent ERK activation. Scale bar, 20 μ m. (j) Quantification of p-ERK intensity in VRK3-
deficient neurons expressing HA (mock), HA-VRK3, HA-HSP70, or HA-HSP70-3NLS as in (i). Values are 
normalized to HA-controls, and shown as mean ± s.d., n ≥ 30 for each sample. Student’s t-test, n.s., not significant, 
***P < 0.001.
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Figure 6. HSP70 expression is increased in brains of AD and PD patients, and especially in AD,  
neurons with HSP70 nuclear localization exhibit less Aβ accumulation and apoptotic cell death.  
(a) ERK activation as well as HSP70 and VRK3 expression were increased in the prefrontal cortex (PFC) of AD 
and PD patients compared with non-demented control individuals. (b) Quantification of HSP70, VRK3 and 
p-ERK in AD, PD, and control brains as in (a). Values are normalized to GAPDH and shown as mean ± s.d., 
n = 4. Student’s t-test, *P < 0.05, **P < 0.01. (c) HSP70 nuclear localization prevented Aβ aggregate formation 
in AD brains. White arrowheads highlight nuclear-localized HSP70. White arrows points cell enlarged. Scale 
bar, 10 μ m. (d) Cytosolic calcium levels are kept low via energy-dependent sequestration into mitochondria and 
endoplasmic reticulum (not shown). Excessive activation of glutamate receptors and the formation of annular 
pores consisting of oligomeric Aβ and α -synuclein in the lipid bilayer lead to membrane permeabilization 
and promote excessive calcium influx. Increased intracellular calcium levels result in calcium overload of 
mitochondria and activation of the Ras/Raf/ERK pathway. Aβ and other amyloidogenic peptides, such as α 
-synuclein, generate ROS from molecular oxygen through electron transfer interactions, and impaired oxidative 
phosphorylation and decreased complex I activity in mitochondria also cause ROS formation ROS further 
impairs the ubiquitin-proteasome system, leading to accelerated accumulation of protein aggregates. In parallel, 
loss of mitochondrial membrane potential and persistent activation of the Ras/Raf/ERK pathway result in the 
release of cytochrome c from the mitochondria into the cytosol, caspase activated, and ultimately, neuronal 
death occurred. VRK3 facilitated nuclear localization of glutamate-induced HSP70. Nuclear HSP70 inhibited 
sustained ERK activation through enhancement of VHR phosphatase activity via direct binding and thereby 
reduced neuronal cell death.
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study showing HSP70-mediated enhancement of VHR phosphatase activity in the absence of ATP indicates that 
HSP70 facilitates VHR phosphatase activity in a chaperone activity-independent manner.
Persistent ERK activation induced by glutamate excitotoxicity and oxidative stress has been considered as one 
of causes to develop neurodegenerative diseases21,22,30. Several studies demonstrate that the upregulation of HSPs 
influences the progression of neurodegenerative disorders56,57 and protects against disease-associated toxicity in 
several neurodegenerative conditions17,18,20. Moreover, recently it has been reported that cyclin-dependent kinase 
5-mediated phosphorylation of VRK3 at Ser 108 suppresses oxidative stress-induced prolonged ERK activation 
and subsequent cell death58. The present study investigated endogenous protective mechanisms mediated by 
HSP70 and VRK3 against glutamate excitotoxicity-induced neuronal cell death. Under physiological conditions, 
VHR is sufficient to regulate ERK activity. However, glutamate-induced excitotoxicity causes abnormal ERK acti-
vation, which impairs cellular stress resistance. Active ERK transcription upregulated both HSP70 and ERK3 
expression to suppress its prolonged activity. Induced HSP70 translocates into the nucleus and enhances ERK 
phosphate VHR activity. VRK3 promoted HSP70 nuclear localization through binding, leading to facilitation on 
HSP70-mediated ERK regulation. Furthermore, increased levels of HSP70 and VRK3 observed in post-mortem 
brain tissue from AD and PD patients, and the nuclear localization of HSP70 is associated with less Aβ accumu-
lation in AD brains.
These results may indicate that HSP70 and VRK3 could be targeted to reduce neurodegeneration. Both mol-
ecules have a protective role against glutamate-induced excitotoxicity in the early stages of neurodegenerative 
disease. Because stress-induced elevation of HSP70 does not occur across the entire brain but only in regions that 
are more susceptible to stress, the accumulation of severe damage in later stages of the disease may be overwhelm-
ing and cross a certain threshold that triggers cell death. These findings suggest a link between the progression of 
neurodegeneration and protective mechanisms against excitotoxicity-induced neuronal death. Therefore, HSP70 
and VRK3 may be useful indicators for diagnosing the progressive stages of AD or PD and serve as therapeutic 
targets in neurodegenerative diseases.
Methods
Brain sample procurement. Post-mortem human brain tissue was procured in accordance with institu-
tional guidelines and approved protocols. Formalin-fixed, paraffin-embedded prefrontal cortical brain samples 
and frozen prefrontal cortical brain samples from adults were obtained from the Netherlands Brain Bank. The 
samples analyzed in this study were strictly defined according to Braak and Braak staging59,60, with control sam-
ples being brains that were completely devoid of Lewy bodies and Aβ pathologies (i.e., Braak and Braak stage 
0–2). The characteristics of these samples are provided in Supplementary Tables S1 and S2.
Protein extraction from human brain tissue. Snap-frozen post-mortem human brain tissue was ground 
and homogenized in Triton lysis buffer (20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton-X, 
2.5 mM sodium pyrophosphate, 1 mM β -glycerophosphate, 1 mM Na3VO4) supplemented with protease inhibi-
tors. Samples were sonicated and centrifuged at 15,000 rpm for 30 min at 4 °C. The supernatant was removed, and 
the protein concentration was determined using Bradford Reagent (AMRESCO). Samples were denatured for 
5 min at 95 °C with SDS sample buffer containing β -mercaptoethanol. Proteins were separated by SDS-PAGE and 
transferred to nitrocellulose membranes. Western blots were quantified by densitometry using ImageJ software.
Immunohistochemistry analysis of human brain tissue. Prefrontal cortical brain sections (4 μ m 
thickness) were cut at regular intervals on glass slides. Paraffin-embedded tissue sections were deparaffinized in 
xylene and then rehydrated with decreasing concentrations of ethanol and placed in water. Sections underwent 
antigen retrieval using citrate buffer (10 mM sodium citrate, pH 6.0) and then were washed and blocked with 
PBS containing 3% bovine serum albumin and 0.2% Triton X-100 for 1 h at room temperature. Primary antibod-
ies were diluted in blocking solution. After overnight incubation, sections were washed three times with PBS. 
Secondary antibodies coupled to Alexa fluorophores were diluted in blocking solution. After 1 h of incubation in 
the dark, sections were washed three times with PBS. For counterstaining, sections were further incubated with 
Hoechst (2 μ g/ml) for 10 min at room temperature and then washed three times with PBS. Slices were mounted 
and visualized by fluorescence microscopy.
Mice. Mice deficient for VRK3 was generated by targeted gene disruption in embryonic stem cells. Specific 
pathogen-free (SPF) VRK3 knockout mice were bred and maintained on a C57BL/6 background. All animals 
were maintained on food and water ad libitum with 12-hr light-dark cycle. Approval of the study protocol was 
obtained from the Pohang University of Science and Technology Institutional Animal Care and Use Committee 
(POSTECH IACUC). All animal experiments were carried out according to the provisions of the Animal Welfare 
Act, PHS Animal Welfare Policy, and the principles of the NIH Guide for the Care and Use of Laboratory 
Animals. All mice were maintained under conventional conditions at the POSTECH animal facility under insti-
tutional guidelines.
Primary neuron cultures and transfection. Cortices were dissected from P0.5 newborn pups of wild-
type and VRK3 knockout mice. Cultured cortical neurons were seeded onto a poly-L-lysine-coated culture 
dishes and were maintained in Neurobasal Medium supplemented with GlutaMAX, B27 supplements, and 
penicillin-streptomycin. Neuronal transfections were performed with Lipofectamine 2000 at 3 days in vitro (DIV) 
according to the manufacturer’s instructions.
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Antibodies. The following monoclonal antibodies were purchased: anti-HSP70, anti-p-ERK, and 
anti-α -synuclein (Abcam); anti-GAPDH (Santa Cruz Biotechnology); anti-VHR (BD Biosciences); anti-HA 
(Roche); anti-Aβ (BioLegend); anti-NeuN (Merck Millipore); anti-HSP70, anti-GST, anti-cleaved caspase-3, 
anti-Bak, and anti-Bax (Cell Signaling Technology). The following polyclonal antibodies were also obtained: 
anti-PSD95 (Abcam); anti-HSP70, anti-VRK3, anti-VHR, anti-p-ERK, anti-ERK, and anti-His (Cell Signaling 
Technology); anti-VRK3 (Atlas antibodies); anti-HA (YPYDVPDYA; Bethyl Laboratories); anti-FLAG (D-8), 
anti-Lamin B, and anti-MAP2 (I-18) (Santa Cruz Biotechnology).
Plasmid construction. The coding regions of VRK3, HSP70, and VHR were amplified by RT-PCR from the 
mRNA of NIH3T3, SH-SY5Y, and HEK293A cells and cloned into pFLAG-CMV2, pcDNA3.1-HA, pGEX4T-1, 
pGEX4T-3, pEGFP-N1, or pProEX-Hta vectors. Partial fragments of HSP70 F1 (amino acids 1-380), F2 (amino 
acids 381-537), and F3 (amino acids 538-642) were cloned into pcDNA3.1-HA and pGEX4T-3 vectors. For 
nuclear expression of HSP70, three tandem repeats of NLS peptides of SV40 large T antigen (PKKKRKV)41 were 
fused to the C-terminus.
Cell culture, transfection, and RNA interference. SH-SY5Y cells were grown in minimal essential 
medium (MEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 100 U/ml each penicillin 
G and streptomycin. Transient transfections were performed by electroporation using a Microporator MP-100 
(Digital Bio) or Neon-Transfection System (Invitrogen). Scrambled siRNA (5′ -CCU ACG CCA CCA AUU UCG 
U(dTdT)-3′ ) was purchased from Upstate Biotechnology (GE Healthcare, Dharmacon). VRK3 siRNA (5′ -GGA 
CAA AUU GCC UUC CCA A (dTdT)-3′). HSP70 siRNA (5′ -GUU UGA GGG CAU CGA CUU CU (dTdT)-3′) 
and VHR siRNA (5′ -GGU CCU UCA UGC ACG UCA A (dTdT)-3′) were purchased from Bioneer.
Inhibitors and glutamate treatment. The transport receptor importin-β inhibitor importazole 
(SML0341, Sigma-Aldrich) and the MEK/ERK inhibitor PD98059 (#9900, Cell Signaling Technology) were dis-
solved in dimethyl sulphoxide (DMSO) to allow addition to cell cultures at a final concentration of 0.1% (v/v) 
DMSO. For inhibition of importin-β , SH-SY5Y cells were pre-treated with 40 μ M importazole for 1 h before 
glutamate treatment. For inhibition of ERK activation, SH-SY5Y cells were pre-treated with 50 μ M PD98059 for 
1 h. L-glutamic acid was dissolved in distilled water. SH-SY5Y cells were treated with 20 mM glutamate for 6 h. 
Cultures of mouse primary cortical neurons were treated with 40 μ M glutamate for 24 h.
RNA isolation and cDNA synthesis. SH-SY5Y cells were lysed with TRI-Solution (Bio Science 
Technology) and the total RNA was extracted after addition of 0.2 volume of chloroform. Samples were mixed 
with vortex, incubated at room temperature for 10 min, and centrifuged at 12,000 g for 15 min at 4 °C. Recovery 
of total RNA was then done by precipitation with 0.5 volume of isopropanol. After 10 min incubation at room 
temperature, samples were centrifuged at 12,000 g for 8 min at 4 °C. The RNA pellet was washed with 75% (v/v) 
ethanol, briefly air-dried, and dissolved in diethylpyrocarbonate (DEPC)-treated water by incubating for 5 min 
at 65 °C. Yield and purity of RNA was determined by NanoDrop 2000 spectrophotometer (Thermo Scientific). 
Following quantification, 1 μ g of each total RNA sample was reverse transcribed using oligo-dT and the 
ImProm-II Reverse Transcription System (Promega) according to the manufacturer’s instructions. For qRT-PCR 
analysis, each cDNA sample was diluted 5 times with nuclease free water.
Design and optimization of RT-qPCR primers. Gene-specific qPCR primers were designed using 
Primer3 (version 0.4.0) and Primer-BLAST (NCBI). Primer specificities were confirmed with the melting- 
curve after amplification by RT-qPCR. Amplicon sizes were checked by 2% agarose gel electrophoresis and 
ethidium bromide staining. The specificity of the primers was further confirmed by amplicon sequencing. 
The sequences of the forward and reverse primers were as follows: endogenous hHSP70, 5′ -TGGAGTCC 
TACGCCTTCAAC-3′ and 5′ -GATGGGGTTACACACCTGCT-3′ ; hVRK3, 5′ -CTATTGCCCAAGT 
GGCAAAC-3′ and 5′ -CTCAGTGTTGGGAAGGCAAT-3′ ; human ribosomal protein L32 (hRPL32), 
5′ -AACCCAGAGGCATTGACAAC-3′ and 5′ -GTTGCACATCAGCAGCACTT-3′ .
Quantitative real-time PCR. The mRNA levels of endogenous genes were detected by quantitative 
real-time PCR using a StepOnePlus Real-Time PCR System (Applied Biosystems) with the FastStart Universal 
SYBR Green Master (Roche Applied Science). A 20 μ l of reaction cocktail was constituted of 3 μ l diluted cDNA, 
10 μ l 2X SYBR Green Master Mix and 0.5 μ l each of the forward and reverse primers. The following amplification 
program was used: polymerase activation at 95 °C for 10 min; 40 repeated cycles of 95 °C for 15 s and 60 °C for 
1 min. A comparative Ct method was used for quantification.
Phosphatase activity assay. For measuring the in vitro phosphatase activity of VHR using the phos-
phatase substrate p-nitrophenyl phosphate (pNPP), 5 μ g of GST-VHR and 10 μ g of His-HSP70 were incubated in 
reaction buffer (50 mM Tris at pH 7.5, 5 mM MgCl2, 0.5 mM DTT, and 150 mM KCl) for 30 min at 30 °C. Purified 
proteins were further incubated with 5 × 30 mM of pNPP (P4744, Sigma-Aldrich) dissolved in recommended 
buffer (1 M diethanolamine at pH 10.4 with 0.5 mM MgCl2) for 2 h at 37 °C. The hydrolysis of the substrate was 
measured at 405 nm using an ELISA reader with Infinite 200 Pro NanoQuant (TECAN). For measuring the in 
vitro phosphatase activity of VHR using recombinant p-ERK2, 1 μ g of GST-VHR and 2 μ g of His-HSP70 were 
incubated in reaction buffer (50 mM Tris at pH 7.5, 5 mM MgCl2, 0.5 mM DTT, and 150 mM KCl) for 30 min 
at 30 °C. Purified proteins were further incubated with 50 ng recombinant p-ERK2 (Merck Millipore) for 1 h at 
37 °C.
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Image processing. General image processing were performed by using Adobe Photoshop 7.0 (Adobe 
Systems Inc.).
Statistical analysis. All of the experiments were performed at least three times. All quantitative data are 
presented as mean ± standard deviation (s.d.). Differences between groups were assessed using Student’s t-tests. 
P-values < 0.05 were considered statistically significant. *P < 0.05, **P < 0.01, ***P < 0.001.
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